Craig-Hallum initiated coverage of Rezolute with a Buy rating and $14 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute announces RZ402 trial meets both primary endpoints
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
- Rezolute reports Q3 EPS (34c), consensus (30c)
- Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
- RZLT Earnings this Week: How Will it Perform?